Phase I, Pilot Study in Healthy Volunteers, to Assess the Safety and Pharmacokinetics of PCO-02, Which Active Ingredient is BPC-157, a Penta-deca-peptide From Gastric Source

PharmaCotherapia d.o.o. · ClinicalTrials.gov registration

The only registered Phase 1 safety and pharmacokinetic study of oral BPC-157 in humans, with adverse events over six months as the primary endpoint. Registry checked 2026-08-15: estimated primary completion February 2016, status still listed as unknown, no results posted and no journal report indexed — a decade after the estimated completion date.

Population

Healthy volunteers, Mexico

Intervention

Oral PCO-02 tablets containing 1 mg BPC-157: single ascending dose, then 3 tablets every 8 hours for two weeks

Comparator

Matched placebo tablets, quadruple-blind

Limitations

No results in the registry or the literature; a record that a trial was registered, not that one reported.